SHAMIR NACHUM
SHAMIR NACHUM's purchase track record
SHAMIR NACHUM has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/3/2026 | MDWD | $84K | -4.9% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MediWound Secures $3.3M U.S. Department of War Grant. MediWound has been awarded an additional $3.3 million by the U.S. Department of War. The funding is intended to advance the development of a room-temperature-stable formulation of its NexoBrid product. This grant supports the company's ongoing research efforts for its lead therapeutic asset.
Transaction History
| STXS | ▲ Buy | Grant | 43,103 | $0 | 7/1/2026 | View on chart |
| MDWD | ▲ Buy | Open Market | 175 | $2K | 6/3/2026 | View on chart |
| MDWD | ▲ Buy | Open Market | 5,825 | $82K | 6/3/2026 | View on chart |
| STXS | ▲ Buy | Grant | 46,948 | $0 | 1/2/2026 | View on chart |
| STXS | ▲ Buy | Grant | 43,668 | $0 | 7/1/2025 | View on chart |
| STXS | ▲ Buy | Grant | 45,608 | $0 | 1/2/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
No recent news for STXS
There are no new developments for Stereotaxis Inc. in the past week. The company continues to trade near its 12‑month low, with an RSI of 22.8 indicating oversold conditions. The 52‑week range remains $1.09 to $3.59, and analysts maintain a target of $3.00.
No recent news for STXS. There are no new developments for Stereotaxis Inc. in the past week. The company continues to trade near its 12‑month low, with an RSI of 22.8 indicating oversold conditions. The 52‑week range remains $1.09 to $3.59, and analysts maintain a target of $3.00.